Filing Details
- Accession Number:
- 0001439222-24-000004
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-09 16:22:09
- Reporting Period:
- 2024-01-05
- Accepted Time:
- 2024-01-09 16:22:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1439222 | Agios Pharmaceuticals Inc. | AGIO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1881190 | Sarah Gheuens | 88 Sidney Street Cambridge MA 02139 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-01-05 | 5,000 | $0.00 | 29,658 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-09 | 1,789 | $22.99 | 27,869 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Performance share units | Disposition | 2024-01-05 | 5,000 | $0.00 | 5,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | M | Direct |
Footnotes
- Includes 499 shares purchased through the Company's employee stock purchase plan.
- Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated September 1, 2021.
- Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
- The PSUs were granted on September 1, 2021. The PSUs vest upon the achievement of a specified clinical milestone. The performance criteria for the specified clinical milestone was determined to have been met on January 5, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
Billionaire Hedge Funds
